Paolo Simioni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5623297/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood, 2002, 100, 3484-3488.	1.4	1,617
2	The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica, 2007, 92, 199-205.	3.5	686
3	COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure. Thrombosis and Haemostasis, 2020, 120, 998-1000.	3.4	553
4	Residual Venous Thrombosis as a Predictive Factor of Recurrent Venous Thromboembolism. Annals of Internal Medicine, 2002, 137, 955.	3.9	457
5	The Risk of Recurrent Venous Thromboembolism in Patients with an Arg ⁵⁰⁶ →Cln Mutation in the Gene for Factor V (Factor V Leiden). New England Journal of Medicine, 1997, 336, 399-403.	27.0	385
6	Impact of Thrombophilia on Risk of Arterial Ischemic Stroke or Cerebral Sinovenous Thrombosis in Neonates and Children. Circulation, 2010, 121, 1838-1847.	1.6	383
7	Incidence of Venous Thromboembolism in Families with Inherited Thrombophilia. Thrombosis and Haemostasis, 1999, 81, 198-202.	3.4	312
8	A simple ultrasound approach for detection of recurrent proximal-vein thrombosis Circulation, 1993, 88, 1730-1735.	1.6	310
9	X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua). New England Journal of Medicine, 2009, 361, 1671-1675.	27.0	298
10	Prospective evaluation of anticoagulation and transjugular intrahepatic portosistemic shunt for the management of portal vein thrombosis in cirrhosis. Liver International, 2012, 32, 919-927.	3.9	284
11	Impact of Inherited Thrombophilia on Venous Thromboembolism in Children. Circulation, 2008, 118, 1373-1382.	1.6	268
12	Different Hypercoagulable Profiles in Patients with COVID-19 Admitted to the Internal Medicine Ward and the Intensive Care Unit. Thrombosis and Haemostasis, 2020, 120, 1474-1477.	3.4	233
13	Frequency of Pregnancy-Related Venous Thromboembolism in Anticoagulant Factor-Deficient Women: Implications for Prophylaxis. Annals of Internal Medicine, 1996, 125, 955.	3.9	187
14	The Risk of Abortion and Stillbirth in Antithrombin-, Protein C-, and Protein S-deficient Women. Thrombosis and Haemostasis, 1996, 75, 387-388.	3.4	182
15	Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematology,the, 2020, 7, e18-e27.	4.6	173
16	The long term clinical course of acute deep vein thrombosis of the arm: prospective cohort study. BMJ: British Medical Journal, 2004, 329, 484-485.	2.3	143
17	Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood, 2008, 112, 3615-3623.	1.4	135
18	The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood, 1999, 94, 3702-6.	1.4	130

#	Article	IF	CITATIONS
19	Promoter Polymorphisms in the Plasma Glutathione Peroxidase (GPx-3) Gene. Stroke, 2007, 38, 41-49.	2.0	128
20	Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood, 2000, 96, 3329-3333.	1.4	127
21	Low-Molecular-Weight Heparin versus Compression Stockings for Thromboprophylaxis after Knee Arthroscopy. Annals of Internal Medicine, 2008, 149, 73.	3.9	126
22	Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. Thrombosis Research, 2011, 127, 473-477.	1.7	122
23	Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms. Blood, 2010, 115, 879-886.	1.4	121
24	Hyperhomocysteinemia and Deep-Vein Thrombosis A Case-Control Study. Thrombosis and Haemostasis, 1996, 76, 0883-0886.	3.4	106
25	The incidence of venous thromboembolism in thrombophilic children: a prospective cohort study. Blood, 2002, 100, 2403-2405.	1.4	101
26	The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. Blood, 2012, 120, 4521-4523.	1.4	100
27	Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study. Blood, 2002, 99, 1938-1942.	1.4	95
28	The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S. Haematologica, 2006, 91, 695-8.	3.5	94
29	Dual polarization of human alveolar macrophages progressively increases with smoking and COPD severity. Respiratory Research, 2017, 18, 40.	3.6	92
30	Ischemic Stroke in Young Patients With Activated Protein C Resistance. Stroke, 1995, 26, 885-890.	2.0	87
31	An In Vitro Analysis of the Combination of Hemophilia A and Factor VLEIDEN. Blood, 1997, 90, 3067-3072.	1.4	86
32	Peculiar whole blood rotation thromboelastometry (Rotem) profile in 40 sideropenic anaemia patients. Thrombosis and Haemostasis, 2008, 100, 1106-1110.	3.4	82
33	Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events. Thrombosis and Haemostasis, 2015, 113, 85-96.	3.4	82
34	Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Archives of Internal Medicine, 1997, 157, 57-62.	3.8	82
35	The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues. British Journal of Cancer, 2019, 121, 359-371.	6.4	78
36	An Antifibrinolytic Mechanism Describing the Prothrombotic Effect Associated with Factor VLeiden. Journal of Biological Chemistry, 1996, 271, 22949-22952.	3.4	74

#	Article	IF	CITATIONS
37	Increased anticoagulant response to lowâ€molecularâ€weight heparin in plasma from patients with advanced cirrhosis. Journal of Thrombosis and Haemostasis, 2012, 10, 1823-1829.	3.8	74
38	The hazard of (sub)therapeutic doses of anticoagulants in nonâ€critically ill patients with Covidâ€19: The Padua province experience. Journal of Thrombosis and Haemostasis, 2020, 18, 2629-2635.	3.8	71
39	Advances in understanding the bleeding diathesis in factor V deficiency. British Journal of Haematology, 2009, 146, 17-26.	2.5	69
40	Hereditary and acquired protein S deficiencies are associated with low TFPI levels in plasma. Journal of Thrombosis and Haemostasis, 2010, 8, 294-300.	3.8	69
41	Severe Arterial Cerebral Thrombosis in a Patient with Protein S Deficiency (Moderately Reduced Total) Tj ETQq1	1 0,784314 3.4	4 rgBT /Overl
42	Platelet-Derived Factor Va/VaLeiden Cofactor Activities Are Sustained on the Surface of Activated Platelets Despite the Presence of Activated Protein C. Blood, 1998, 91, 2818-2829.	1.4	68
43	"Pseudo Homozygous―Activated Protein C Resistance due to Double Heterozygous Factor V Defects (Factor V Leiden Mutation and Type I Quantitative Factor V Defect) Associated with Thrombosis: Report of Two Cases Belonging to Two Unrelated Kindreds. Thrombosis and Haemostasis, 1996, 75, 422-426.	3.4	67
44	Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. Digestive and Liver Disease, 2017, 49, 440-445.	0.9	66
45	Prothrombin fragment 1+2 and thrombin–antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation. British Journal of Haematology, 1996, 92, 435-441.	2.5	64
46	The PAI-I gene 4G/5G Polymorphism and Deep Vein Thrombosis in Patients with Inherited Thrombophilia. Clinical and Applied Thrombosis/Hemostasis, 2003, 9, 299-307.	1.7	64
47	Critical Review of the Evolution of Extracellular Vesicles' Knowledge: From 1946 to Today. International Journal of Molecular Sciences, 2021, 22, 6417.	4.1	64
48	Antiplatelet Therapy and Other Interventions after Revascularisation Procedures in Patients with Peripheral Arterial Disease: a Meta-analysis. European Journal of Vascular and Endovascular Surgery, 2000, 19, 370-380.	1.5	62
49	Megakaryocytes endocytose and subsequently modify human factor V in vivo to form the entire pool of a unique platelet-derived cofactor. Journal of Thrombosis and Haemostasis, 2005, 3, 450-456.	3.8	62
50	Inherited Thrombophilia and Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2006, 32, 700-708.	2.7	62
51	miR-30c-5p regulates macrophage-mediated inflammation and pro-atherosclerosis pathways. Cardiovascular Research, 2017, 113, 1627-1638.	3.8	62
52	Recurrence of venous thromboembolism in patients with familial thrombophilia. Archives of Internal Medicine, 1997, 157, 2227-2232.	3.8	62
53	Deep Venous Thrombosis and Lupus Anticoagulant. Thrombosis and Haemostasis, 1996, 76, 187-189.	3.4	61
54	Acute Kidney Injury in Decompensated Cirrhosis Is Associated With Both Hypoâ€coagulable and Hyperâ€coagulable Features. Hepatology, 2020, 72, 1327-1340.	7.3	60

#	Article	IF	CITATIONS
55	Hypercoagulability detected by whole blood thromboelastometry (ROTEM®) and impedance aggregometry (MULTIPLATE®) in obese patients. Thrombosis Research, 2015, 135, 548-553.	1.7	59
56	A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. European Journal of Gastroenterology and Hepatology, 2019, 31, 34-42.	1.6	58
57	Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis. Liver International, 2012, 32, 1465-1476.	3.9	55
58	Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role. Thrombosis and Haemostasis, 2013, 110, 378-385.	3.4	55
59	Circulating levels and characterization of microparticles in patients with different degrees of glucose tolerance. Cardiovascular Diabetology, 2017, 16, 118.	6.8	55
60	COVID-19–Associated Coagulopathy and Inflammatory Response: What Do We Know Already and What Are the Knowledge Gaps?. Anesthesia and Analgesia, 2020, 131, 1324-1333.	2.2	55
61	Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. British Journal of Haematology, 1998, 103, 1045-1050.	2.5	54
62	Combinations of 4 mutations (FV R506Q, FV H1299R, FV Y1702C, PT 20210G/A) affecting the prothrombinase complex in a thrombophilic family. Blood, 2000, 96, 1443-1448.	1.4	54
63	Clinical Data of Neonatal Systemic Thrombosis. Journal of Pediatrics, 2016, 171, 60-66.e1.	1.8	54
64	Thrombophilia, risk factors and prevention. Expert Review of Hematology, 2019, 12, 147-158.	2.2	54
65	An underestimated combination of opposites resulting in enhanced thrombotic tendency. Blood, 2005, 106, 2363-2365.	1.4	52
66	Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. Cancers, 2018, 10, 450.	3.7	51
67	Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Lancet Haematology,the, 2019, 6, e500-e509.	4.6	51
68	The Risk of Fetal Loss in Family Members of Probands with Factor V Leiden Mutation. Thrombosis and Haemostasis, 1999, 82, 1237-1239.	3.4	50
69	Impact of Persistent Antiphospholipid Antibodies on Risk of Incident Symptomatic Thromboembolism in Children: A Systematic Review and Meta-Analysis. Seminars in Thrombosis and Hemostasis, 2011, 37, 802-809.	2.7	50
70	Incidence of venous thromboembolism in families with inherited thrombophilia. Thrombosis and Haemostasis, 1999, 81, 198-202.	3.4	50
71	New Prothrombin Mutation (Arg596Trp, Prothrombin Padua 2) Associated With Venous Thromboembolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1022-1029.	2.4	49
72	Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). Blood Advances, 2020, 4, 6250-6258.	5.2	49

#	Article	IF	CITATIONS
73	Thromboelastometry for guiding bleeding management of the critically ill patient: a systematic review of the literature. Minerva Anestesiologica, 2014, 80, 1320-35.	1.0	49
74	Screening for thrombophilia and antithrombotic prophylaxis in pregnancy: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thrombosis Research, 2009, 124, e19-e25.	1.7	48
75	Increased Tissue Factor-initiated Prothrombin Activation as a Result of the Arg506 → Gln Mutation in Factor VLEIDEN. Journal of Biological Chemistry, 1997, 272, 20721-20729.	3.4	47
76	Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency. Haematologica, 2010, 95, 1563-1571.	3.5	47
77	Thrombin generationâ€based assays to measure the activity of the TFPl–protein S pathway in plasma from normal and protein Sâ€deficient individuals. Journal of Thrombosis and Haemostasis, 2010, 8, 750-758.	3.8	47
78	Microparticles as biomarkers of venous thromboembolic events. Biomarkers in Medicine, 2016, 10, 743-755.	1.4	46
79	COVIDâ€19 and Venous Thromboembolism in Intensive Care or Medical Ward. Clinical and Translational Science, 2020, 13, 1108-1114.	3.1	46
80	Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. Hepatology, 2021, 73, 1275-1289.	7.3	45
81	Contact System Activation and Cancer: New Insights in the Pathophysiology of Cancer-Associated Thrombosis. Thrombosis and Haemostasis, 2018, 118, 251-265.	3.4	44
82	Whole blood coagulation assessment using rotation thrombelastogram thromboelastometry in patients with acute deep vein thrombosis. Blood Coagulation and Fibrinolysis, 2008, 19, 355-360.	1.0	43
83	Antiphospholipid Antibodies, Recurrent Thromboembolism, and Intensity of Warfarin Anticoagulation. Thrombosis and Haemostasis, 1996, 75, 859-859.	3.4	43
84	Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death. Journal of Hepatology, 2022, 77, 660-669.	3.7	43
85	ACCURACY OF TWO NEWLY DESCRIBED D-DIMER TESTS IN PATIENTS WITH SUSPECTED DEEP VENOUS THROMBOSIS. Thrombosis Research, 1997, 86, 93-99.	1.7	42
86	Detection and characterization of seven novel protein S (PROS) gene lesions: evaluation of reverse transcript-polymerase chain reaction as a mutation screening strategy. Blood, 1995, 86, 2632-2641.	1.4	41
87	Endothelial Damage of the Portal Vein is Associated with Heparin-Like Effect in Advanced Stages of Cirrhosis. Thrombosis and Haemostasis, 2020, 120, 1173-1181.	3.4	41
88	Thrombin generation in patients with COVID-19 with and without thromboprophylaxis. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1323-1330.	2.3	40
89	Whole blood rotation thromboelastometry (ROTEM®) profiles in subjects with non-neoplastic portal vein thrombosis. Thrombosis Research, 2013, 132, e131-e134.	1.7	39
90	Diagnosis and management of <i>factor V Leiden</i> . Expert Review of Hematology, 2016, 9, 1139-1149.	2.2	39

#	Article	IF	CITATIONS
91	Reversal of hypercoagulability in patients with <scp>HCV</scp> â€related cirrhosis after treatment with directâ€acting antivirals. Liver International, 2018, 38, 2210-2218.	3.9	39
92	Increased Cardiovascular Risk Associated with Chemical Sensitivity to Perfluoro–Octanoic Acid: Role of Impaired Platelet Aggregation. International Journal of Molecular Sciences, 2020, 21, 399.	4.1	39
93	Upper extremity deep vein thrombosis. Internal and Emergency Medicine, 2010, 5, 103-109.	2.0	38
94	Homozygous F5 deepâ€intronic splicing mutation resulting in severe factor V deficiency and undetectable thrombin generation in plateletâ€rich plasma. Journal of Thrombosis and Haemostasis, 2011, 9, 959-968.	3.8	38
95	Life-threatening coagulopathy and hypofibrinogenaemia induced by tigecycline in a patient with advanced liver cirrhosis. European Journal of Gastroenterology and Hepatology, 2014, 26, 681-684.	1.6	38
96	Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. Clinica Chimica Acta, 2015, 446, 201-205.	1.1	38
97	Albumin uptake in human podocytes: a possible role for the cubilin-amnionless (CUBAM) complex. Scientific Reports, 2017, 7, 13705.	3.3	38
98	Factor V Leiden mutation and the risk of venous thromboembolism in pregnant women. Haematologica, 2001, 86, 1305-9.	3.5	38
99	Isolation and characterization of an antifactor V antibody causing activated protein C resistance from a patient with severe thrombotic manifestations. Blood, 2002, 99, 3985-3992.	1.4	37
100	Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia. Journal of Thrombosis and Haemostasis, 2007, 5, 971-979.	3.8	37
101	Selective modulation of protein C affinity for EPCR and phospholipids by Gla domain mutation. FEBS Journal, 2005, 272, 97-108.	4.7	36
102	Circulating microparticles and the risk of thrombosis in inherited deficiencies of antithrombin, protein C and protein S. Thrombosis and Haemostasis, 2016, 115, 81-88.	3.4	36
103	Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. Archives of Internal Medicine, 1994, 154, 164-168.	3.8	36
104	Reduced Clot Stability by Thromboelastography as a Potential Indicator of Procedureâ€Related Bleeding in Decompensated Cirrhosis. Hepatology Communications, 2021, 5, 272-282.	4.3	35
105	Dynamics of circulating microparticles in obesity after weight loss. Internal and Emergency Medicine, 2016, 11, 695-702.	2.0	34
106	Activated Plateletâ€Derived and Leukocyteâ€Derived Circulating Microparticles and the Risk of Thrombosis in Heparinâ€Induced Thrombocytopenia: A Role for PF4â€Bearing Microparticles?. Cytometry Part B - Clinical Cytometry, 2018, 94, 334-341.	1.5	34
107	Thrombosis and Thrombophilia in Children: A Systematic Review. Seminars in Thrombosis and Hemostasis, 2006, 32, 724-728.	2.7	32
108	Factor VIIa-antithrombin complexes in patients with arterial and venous thrombosis. Thrombosis and Haemostasis, 2010, 103, 1188-1192.	3.4	32

#	Article	lF	CITATIONS
109	The antiproliferative effects of ouabain and everolimus on adrenocortical tumor cells. Endocrine Journal, 2014, 61, 41-53.	1.6	32
110	Circulating microparticles in umbilical cord blood in normal pregnancy and pregnancy with preeclampsia. Thrombosis Research, 2015, 136, 427-431.	1.7	32
111	The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein I antibodies. A comparison with a homemade ELISA method. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1083-9.	2.3	32
112	ABO blood groups and the risk of venous thrombosis in patients with inherited thrombophilia. Blood Transfusion, 2013, 11, 250-3.	0.4	32
113	Thromboembolic disease developing during oral contraceptive therapy in young females with antiphospholipid antibodies. Blood Coagulation and Fibrinolysis, 1996, 7, 497-501.	1.0	31
114	Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation. Journal of Thrombosis and Haemostasis, 2005, 3, 2695-2702.	3.8	31
115	In vitro and in vivo effects of the carbon monoxideâ€releasing molecule, CORMâ€3, in the xenogeneic pigâ€toâ€primate context. Xenotransplantation, 2009, 16, 99-114.	2.8	31
116	Cell Therapy for Parkinson's Disease: A Translational Approach to Assess the Role of Local and Systemic Immunosuppression. American Journal of Transplantation, 2016, 16, 2016-2029.	4.7	31
117	Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study. Journal of the American Heart Association, 2020, 9, e018917.	3.7	31
118	Coagulation and plasma fibronectin parameters in HELLP syndrome. International Journal of Gynecology and Obstetrics, 1995, 50, 263-268.	2.3	30
119	Molecular Bases of Pseudo-homozygous APC Resistance: The Compound Heterozygosity for FV R506Q and a FV Null Mutation Results in the Exclusive Presence of FV Leiden Molecules in Plasma. Thrombosis and Haemostasis, 1998, 80, 403-406.	3.4	29
120	Effects of Long-term Administration of High-dose Recombinant Human Antithrombin in Immunosuppressed Primate Recipients of Porcine Xenografts. Transplantation, 2005, 80, 1501-1510.	1.0	29
121	Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis. Thrombosis Research, 2016, 143, 118-121.	1.7	29
122	Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acuteâ€onâ€chronic liver failure. Liver International, 2021, 41, 2455-2466.	3.9	29
123	Gender and the Risk of Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2011, 37, 193-198.	2.7	28
124	Paediatric arterial ischaemic stroke and cerebral sinovenous thrombosis. Thrombosis and Haemostasis, 2015, 113, 1270-1277.	3.4	28
125	The Utility of Non-invasive Tests for Detection of Previous Proximal-vein Thrombosis. Thrombosis and Haemostasis, 1995, 73, 592-596.	3.4	28
126	High prevalence of inherited thrombophilia in â€~presumed peri-neonatal' ischemic stroke. European Journal of Haematology, 2007, 80, 071119183417002-???.	2.2	27

#	Article	IF	CITATIONS
127	Circulating microparticles in carriers of factor V Leiden with and without a history of venous thrombosis. Thrombosis and Haemostasis, 2012, 108, 633-639.	3.4	27
128	Global reporting of pulmonary embolism–related deaths in the World Health Organization mortality database: Vital registration data from 123Âcountries. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12520.	2.3	27
129	Longitudinal Trend of Plasma Concentrations of Extracellular Vesicles in Patients Hospitalized for COVID-19. Frontiers in Cell and Developmental Biology, 2021, 9, 770463.	3.7	27
130	Necroptosis-driving genes <i>RIPK1, RIPK3</i> and <i>MLKL-p</i> are associated with intratumoral CD3 ⁺ and CD8 ⁺ T cell density and predict prognosis in hepatocellular carcinoma. , 2022, 10, e004031.		27
131	Effect of delivery modalities on the physiologic inhibition system of coagulation of the neonate. Thrombosis Research, 2002, 105, 15-18.	1.7	26
132	Patient blood management in cardiac surgery: The "Granducato algorithm― International Journal of Cardiology, 2019, 289, 37-42.	1.7	26
133	Levels of circulating microparticles in septic shock and sepsis-related complications: a case-control study. Minerva Anestesiologica, 2019, 85, 625-634.	1.0	26
134	The role of drugs, particularly oral contraceptives, in triggering thrombosis in congenital defects of coagulation and Fibrinolysis, 1991, 2, 673-678.	1.0	25
135	Childhood stroke associated with familial protein S deficiency. Brain and Development, 1994, 16, 241-245.	1.1	25
136	A Dysfunctional Factor X (Factor X San Giovanni Rotondo) Present at Homozygous and Double Heterozygous Level: Identification of a Novel Microdeletion (delC556) and Missense Mutation (Lys408→Asn) in the Factor X Gene. Thrombosis Research, 2001, 101, 219-230.	1.7	25
137	Alterations in the Coagulation Profile in Renal Pig-to-Monkey Xenotransplantation. American Journal of Transplantation, 2004, 4, 335-345.	4.7	25
138	A novel dysfunctional protein C (Protein C Padua 2) associated with a thrombotic tendency: substitution of Cys for Argâ€1 results in a strongly reduced affinity for binding of Ca ⁺⁺ . British Journal of Haematology, 1993, 85, 521-527.	2.5	25
139	Thrombophilia as a predictor of persistent residual vein thrombosis. Haematologica, 2008, 93, 479-480.	3.5	25
140	Obstetric complications and pregnancy-related venous thromboembolism: The effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation. Thrombosis and Haemostasis, 2012, 107, 477-484.	3.4	25
141	Prothrombin and the prothrombin 20210 G to A polymorphism: their relationship with hypercoagulability and thrombosis. Blood Reviews, 1999, 13, 205-210.	5.7	24
142	The molecular genetics of familial venous thrombosis. Best Practice and Research in Clinical Haematology, 1999, 12, 479-503.	1.7	24
143	Whole blood rotation thromboelastometry (ROTEM ^{\hat{A}^{\otimes}}) in nine severe factor V deficient patients and evaluation of the role of intraplatelets factor V. Haemophilia, 2012, 18, 463-468.	2.1	24
144	Pregnancy-related Recurrent Events in Thrombophilic Women with Previous Venous Thromboembolism. Thrombosis and Haemostasis, 2001, 86, 929-929.	3.4	23

#	Article	IF	CITATIONS
145	Short-term exposure to high levels of air pollution as a risk factor for acute isolated pulmonary embolism. Thrombosis Research, 2014, 134, 259-263.	1.7	23
146	Synergistic antitumour activity of <scp>RAF</scp> 265 and <scp>ZSTK</scp> 474 on human <scp>TT</scp> medullary thyroid cancer cells. Journal of Cellular and Molecular Medicine, 2015, 19, 2244-2252.	3.6	23
147	No evidence for increased platelet activation in patients with hepatitis B- or C-related cirrhosis and hepatocellular carcinoma. Thrombosis Research, 2015, 135, 292-297.	1.7	23
148	Bortezomib, C1-Inhibitor and Plasma Exchange Do Not Prolong the Survival of Multi-Transgenic GalT-KO Pig Kidney Xenografts in Baboons. American Journal of Transplantation, 2015, 15, 358-370.	4.7	23
149	The current understanding of trauma-induced coagulopathy (TIC): a focused review on pathophysiology. Internal and Emergency Medicine, 2017, 12, 981-991.	2.0	23
150	Development and application of global assays of hyper―and hypofibrinolysis. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 46-53.	2.3	23
151	Mutations which Introduce Free Cysteine Residues in the Gla-Domain of Vitamin K Dependent Proteins Result in the Formation of Complexes with α1-Microglobulin. Thrombosis and Haemostasis, 1996, 75, 070-075.	3.4	23
152	Partial gene deletion in a family with factor X deficiency. Blood, 1989, 73, 2123-2127.	1.4	22
153	Hereditary heparin cofactor II deficiency and thrombosis. Blood Coagulation and Fibrinolysis, 1990, 1, 351-556.	1.0	22
154	Clotting inhibitors and fibronectin as potential markers in preeclampsia. International Journal of Gynecology and Obstetrics, 1994, 47, 215-221.	2.3	22
155	Fibronectin and antithrombin as markers of pre-eclampsia in pregnancy. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1996, 70, 33-39.	1.1	22
156	Procoagulant activity in children with community acquired pneumonia, pleural effusion and empyema. Pediatric Pulmonology, 2008, 43, 472-475.	2.0	22
157	Thrombin generation in Cushing's Syndrome: do the conventional clotting indices tell the whole truth?. Pituitary, 2014, 17, 68-75.	2.9	22
158	Characterization of an apparently synonymous <i>F5</i> mutation causing aberrant splicing and factor V deficiency. Haemophilia, 2015, 21, 241-248.	2.1	22
159	Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study. Thrombosis Research, 2021, 205, 24-28.	1.7	22
160	Factor V Leiden and prothrombin gene mutation in inflammatory bowel disease in Mediterranean area. Digestive and Liver Disease, 2001, 33, 559-562.	0.9	21
161	Soluble endothelial protein C receptor (sEPCR) levels and venous thromboembolism in carriers of two dysfunctional protein C variants. Thrombosis Research, 2006, 117, 523-528.	1.7	21
162	Platelet-primed interactions of coagulation and anticoagulation pathways in flow-dependent thrombus formation. Scientific Reports, 2020, 10, 11910.	3.3	21

#	Article	IF	CITATIONS
163	Influence of Hepatocellular Carcinoma on Platelet Aggregation in Cirrhosis. Cancers, 2021, 13, 1150.	3.7	21
164	Peculiar whole blood rotation thromboelastometry (Rotem) profile in 40 sideropenic anaemia patients. Thrombosis and Haemostasis, 2008, 100, 1106-10.	3.4	21
165	The role of antiphospholipid antibodies toward the protein C/protein S system in venous thromboembolic disease. American Journal of Hematology, 2009, 84, 594-596.	4.1	20
166	Reference values for thromboelastometry (ROTEM®) in cynomolgus monkeys (Macaca fascicularis). Thrombosis Research, 2010, 126, e294-e297.	1.7	20
167	Evaluation of a procoagulant phospholipid functional assay as a routine test for measuring circulating microparticle activity. Blood Coagulation and Fibrinolysis, 2014, 25, 534-537.	1.0	20
168	Partial <i>F8</i> gene duplication (factor VIII Padua) associated with high factor VIII levels and familial thrombophilia. Blood, 2021, 137, 2383-2393.	1.4	20
169	Thrombophilic screening in young patients (<40years) with idiopathic ischemic stroke: A controlled study. Thrombosis Research, 2011, 127, 85-90.	1.7	19
170	Use of Glucocorticoids and Risk of Venous Thromboembolism: A Narrative Review. Seminars in Thrombosis and Hemostasis, 2021, 47, 654-661.	2.7	19
171	Venous and arterial thrombophilia. Haematologica, 1997, 82, 96-100.	3.5	19
172	Letter to the editor: Spurious protein C deficiency due to antiphospholipid antibodies. American Journal of Hematology, 1991, 36, 299-300.	4.1	18
173	Phenotype and Genotype Expression in Pseudohomozygous Factor VLEIDEN. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 336-342.	2.4	18
174	Seasonal Variation in the Incidence of Deep Vein Thrombosis in Patients With Deficiency of Protein C or Protein S. Clinical and Applied Thrombosis/Hemostasis, 2002, 8, 231-237.	1.7	18
175	Perioperative coagulation assessment of patients undergoing major elective orthopedic surgery. Internal and Emergency Medicine, 2016, 11, 793-801.	2.0	18
176	The Coagulative Profile of Cyanotic Children Undergoing Cardiac Surgery: The Role of Whole Blood Preoperative Thromboelastometry on Postoperative Transfusion Requirement. Artificial Organs, 2016, 40, 698-705.	1.9	18
177	"In vitro―correction of the severe factor V deficiencyâ€related coagulopathy by a novel plasmaâ€derived factor V concentrate. Haemophilia, 2018, 24, 648-656.	2.1	18
178	Factor V Has Anticoagulant Activity in Plasma in the Presence of TFPIα: Difference between FV1 and FV2. Thrombosis and Haemostasis, 2018, 118, 1194-1202.	3.4	18
179	Microvesicles in bronchoalveolar lavage as a potential biomarker of COPD. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 320, L241-L245.	2.9	18
180	Compound heterozygous protein C deficiency resulting in the presence of only the beta-form of protein C in plasma. Blood, 1996, 88, 2101-2108.	1.4	18

#	Article	IF	CITATIONS
181	Homozygous patients with APC resistance may remain paucisymptomatic or asymptomatic during oral contraception. Blood Coagulation and Fibrinolysis, 1996, 7, 590-594.	1.0	17
182	Asymptomatic Homozygous nt 20210 G to A Prothrombin Polymorphism in Two Blood Donors Belonging to Two Different Kindreds. Clinical and Applied Thrombosis/Hemostasis, 1999, 5, 48-51.	1.7	17
183	Antisense-based RNA therapy of factor V deficiency: in vitro and ex vivo rescue of a F5 deep-intronic splicing mutation. Blood, 2013, 122, 3825-3831.	1.4	17
184	Influence of single nucleotide polymorphisms on thrombin generation in factor V Leiden heterozygotes. Thrombosis and Haemostasis, 2014, 111, 438-446.	3.4	17
185	Fibrinogen γ′ increases the sensitivity to activated protein C in normal and factor V Leiden plasma. Blood, 2014, 124, 1531-1538.	1.4	17
186	Acute kidney injury is associated with increased levels of circulating microvesicles in patients with decompensated cirrhosis. Digestive and Liver Disease, 2021, 53, 879-888.	0.9	17
187	Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications. Liver International, 2022, 42, 1229-1240.	3.9	17
188	Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections. JHEP Reports, 2022, 4, 100493.	4.9	17
189	A new global test for the evaluation of the protein C???protein S system. Blood Coagulation and Fibrinolysis, 1996, 7, 465-469.	1.0	16
190	Hemorrhagic and thrombotic disorders due to factor V deficiencies and abnormalities: an updated classification. Blood Reviews, 1998, 12, 45-51.	5.7	16
191	The G20210A prothrombin gene mutation: is there room for screening families?. Journal of Thrombosis and Haemostasis, 2004, 2, 1487-1488.	3.8	16
192	Whole blood thromboelastometry profiles in women with preeclampsia. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1793-8.	2.3	16
193	Origin and levels of circulating microparticles in normal pregnancy: A longitudinal observation in healthy women. Scandinavian Journal of Clinical and Laboratory Investigation, 2015, 75, 487-495.	1.2	16
194	More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC. Hepatology Communications, 2021, 5, 1987-2000.	4.3	16
195	Two Additional Homozygous Patients for the 20210 Prothrombin Polymorphism with No Venous Thrombosis. Thrombosis Research, 1999, 96, 415-417.	1.7	15
196	Activated Protein C Resistance in Normal and Pre-Eclamptic Pregnancies. Gynecologic and Obstetric Investigation, 2002, 54, 145-149.	1.6	15
197	The incidence of venous thromboembolism in carriers of antithrombin, protein C or protein S deficiency associated with the HR2 haplotype of factor V: a family cohort study. Journal of Thrombosis and Haemostasis, 2005, 3, 1414-1420.	3.8	15
198	Varicella and Stroke in Children. Clinical and Applied Thrombosis/Hemostasis, 2011, 17, E127-E130.	1.7	15

#	Article	IF	CITATIONS
199	High dose of human plasmaâ€derived FVIIIâ€VWF as firstâ€line therapy in patients affected by acquired haemophilia A and concomitant cardiovascular disease: four case reports and a literature review. Haemophilia, 2013, 19, e50-3.	2.1	15
200	Does decreased fibrinolysis have a role to play in the development of non-neoplastic portal vein thrombosis in patients with hepatic cirrhosis?. Internal and Emergency Medicine, 2014, 9, 397-403.	2.0	15
201	Comparison of Fondaparinux and Low-Molecular-Weight Heparin in the Treatment of Portal Vein Thrombosis in Cirrhosis. American Journal of Medicine, 2021, 134, 1278-1285.e2.	1.5	15
202	Low Rate of Venous Thromboembolism in Asymptomatic Relatives of Probands with Factor V Leiden Mutation. Annals of Internal Medicine, 1999, 130, 538.	3.9	15
203	Symptomatic combined homozygous factor XII deficiency and heterozygous factor V Leiden. luscaber@tin.it. Journal of Thrombosis and Thrombolysis, 2000, 9, 271-275.	2.1	14
204	Postthrombotic Syndrome: Incidence, Prevention, and Management. Seminars in Vascular Medicine, 2001, 01, 071-080.	2.1	14
205	Circulating microparticles in carriers of prothrombin C20210A mutation. Thrombosis and Haemostasis, 2014, 112, 432-437.	3.4	14
206	Levels of angiogenic proteins in plasma and platelets are not different between patients with hepatitis B/C-related cirrhosis and patients with cirrhosis and hepatocellular carcinoma. Platelets, 2015, 26, 577-582.	2.3	14
207	Thromboelastometry guided fibrinogen replacement therapy in cardiac surgery: a retrospective observational study. Journal of Anesthesia, 2017, 31, 286-290.	1.7	14
208	Are thromboelastometric and thromboelastographic parameters associated with mortality in septic patients? A systematic review and meta-analysis. Journal of Critical Care, 2021, 61, 5-13.	2.2	14
209	Oral contraceptives caused thrombosis in a monoovular twin with protein C deficiency, while the other, without medication, remained asymptomatic. Blood Coagulation and Fibrinolysis, 1992, 3, 119-120.	1.0	13
210	Risk of recurrent venous thromboembolism and thrombophilia: does discrepancy make complexity or vice versa?. Journal of Thrombosis and Haemostasis, 2003, 1, 16-18.	3.8	13
211	Who should be tested for thrombophilia?. Current Opinion in Hematology, 2006, 13, 337-343.	2.5	13
212	Effects of Long-Term Administration of Recombinant Human Protein C in Xenografted Primates. Transplantation, 2011, 91, 161-168.	1.0	13
213	Freedom Solo Stentless Aortic Valve: Quantitative and Qualitative Assessment of Thrombocytopenia. Annals of Thoracic Surgery, 2011, 92, 1935.	1.3	13
214	Factor VIIa-antithrombin complex: a possible new biomarker for activated coagulation. Clinical Chemistry and Laboratory Medicine, 2017, 55, 484-488.	2.3	13
215	Whole-blood hypocoagulable profile correlates with a greater risk of death within 28 days in patients with severe sepsis. Korean Journal of Anesthesiology, 2020, 73, 224-231.	2.5	13
216	Impact of COVID-19 and COVID-19 vaccination on high-risk patients with antiphospholipid syndrome: a nationwide survey. Rheumatology, 2022, 61, SI136-SI142.	1.9	13

#	Article	IF	CITATIONS
217	Evaluation of activated protein C resistance in stored plasma. Lancet, The, 1994, 343, 1288-1290.	13.7	12
218	The G20210A prothrombin variant and the risk of venous thromboembolism or fetal loss in pregnant women: a family study. Journal of Thrombosis and Haemostasis, 2007, 5, 2193-2196.	3.8	12
219	Duration of anticoagulation and risk of recurrent thromboembolism in carriers of factor V Leiden or prothrombin mutation. Journal of Thrombosis and Haemostasis, 2008, 6, 2223-2224.	3.8	12
220	Whole blood rotation thrombelastometry in subjects undergoing vitamin K antagonist treatment: hypo- or hypercoagulable profiles?. Thrombosis Research, 2008, 122, 568-569.	1.7	12
221	Thromboelastometry profiles in patients undergoing thrombolytic therapy for acute ischaemic stroke. Thrombosis and Haemostasis, 2016, 115, 1231-1234.	3.4	12
222	Changes in plasma circulating microvesicles in patients with HCVâ€related cirrhosis after treatment with directâ€acting antivirals. Liver International, 2020, 40, 913-920.	3.9	12
223	More Severe Hypercoagulable State in Acute COVID-19 Pneumonia as Compared With Other Pneumonia. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2020, 4, 696-702.	2.4	12
224	Platelet-Derived Microparticles Bearing PF4 and Anti-GAGS Immunoglobulins in Patients with Sepsis. Diagnostics, 2020, 10, 627.	2.6	12
225	PAR-4/Ca2+-calpain pathway activation stimulates platelet-derived microparticles in hyperglycemic type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 77.	6.8	12
226	Studies on Coagulation Incompatibilities for Xenotransplantation. Methods in Molecular Biology, 2012, 885, 71-89.	0.9	12
227	Sounds Stimulation on In Vitro HL1 Cells: A Pilot Study and a Theoretical Physical Model. International Journal of Molecular Sciences, 2021, 22, 156.	4.1	12
228	Heterozygous Protein-S Deficiency: A Study of a Large Kindred. Acta Haematologica, 1990, 84, 162-168.	1.4	11
229	Factor V Leiden is associated with more distal location of deep vein thrombosis of the leg. Journal of Thrombosis and Haemostasis, 2008, 6, 544-545.	3.8	11
230	Cerebral sinovenous thrombosis in children: Thrombophilia and clinical outcome. Thrombosis Research, 2008, 121, 589-591.	1.7	11
231	Genetic modulation of the FVLeiden/normal FV ratio and risk of venous thrombosis in factor V Leiden heterozygotes. Journal of Thrombosis and Haemostasis, 2012, 10, 73-80.	3.8	11
232	Tyrosine Kinase Inhibitor Sunitinib Delays Platelet-Induced Coagulation: Additive Effects of Aspirin. Thrombosis and Haemostasis, 2022, 122, 092-104.	3.4	11
233	Factor V Leiden and Thrombophilia. New England Journal of Medicine, 1995, 332, 1381-1384.	27.0	10
234	State-of-the-Art-Review : Combined Heterozygous Plasminogen Deficiency and Factor V Leiden Defect in the Same Kindred. Clinical and Applied Thrombosis/Hemostasis, 2000, 6, 36-40.	1.7	10

#	Article	IF	CITATIONS
235	Long-Term Use of Oral Contraceptive Therapy in Women With the Prothrombin 20210 G-A Polymorphism Without Thrombotic Complications: A Study of 13 Women (12 Heterozygotes and 1) Tj ETQq1 I	10.784314	rg BT /Overlo
236	Abnormal Propeptide Processing Resulting in the Presence of Two Abnormal Species of Protein C in Plasma. Thrombosis and Haemostasis, 2001, 86, 1017-1022.	3.4	10
237	A matrix-assisted laser desorption/ionization time-of-flight based method for screening the 1691G → A mutation in the factor V gene. Blood Coagulation and Fibrinolysis, 2002, 13, 117-122.	1.0	10
238	Factor VIIa-antithrombin complexes in children with ischemic stroke. Thrombosis Research, 2011, 128, 303-304.	1.7	10
239	Thrombophilic risk of individuals with rare compound factor V Leiden and prothrombin G20210A polymorphisms: an international case series of 100 individuals. European Journal of Haematology, 2016, 97, 353-360.	2.2	10
240	New functional assays to selectively quantify the activated protein C―and tissue factor pathway inhibitorâ€cofactor activities of protein S in plasma. Journal of Thrombosis and Haemostasis, 2017, 15, 950-960.	3.8	10
241	Association between ascites and primary hyperfibrinolysis: A cohort study in 210 dogs. Veterinary Journal, 2017, 223, 12-20.	1.7	10
242	Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. Vascular Pharmacology, 2020, 130, 106682.	2.1	10
243	"Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Thrombosis and Haemostasis, 1996, 75, 422-6.	3.4	10
244	Changing Features of Proximal Vein Thrombosis Over Time. Angiology, 1994, 45, 377-382.	1.8	9
245	The effect of pre-eclampsia on the levels of coagulation and fibrinolysis factors in umbilical cord blood of newborns. Blood Coagulation and Fibrinolysis, 2005, 16, 177-181.	1.0	9
246	The Risk of Cancer Progression in Women With Gynecological Malignancies and Thrombophilic Polymorphisms: A Pilot Case-Control Study. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 535-539.	1.7	9
247	Thromboelastographic evaluation of coagulative profiles in pig-to-monkey kidney xenotransplantation. Xenotransplantation, 2013, 20, 89-99.	2.8	9
248	Influence of proband's characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G20210A polymorphisms. Blood, 2013, 122, 2555-2561.	1.4	9
249	Clinical and laboratory characteristics of isolated lupus anticoagulants. Thrombosis Research, 2018, 165, 51-53.	1.7	9
250	Effect of sugammadex on coagulation as detected by rotational thromboelastometry in morbidly obese patients. Minerva Anestesiologica, 2018, 84, 178-188.	1.0	9
251	Cardiopulmonary bypassâ€induced coagulopathy in pediatric patients: The role of platelets in postoperative bleeding. A preliminary study. Artificial Organs, 2021, 45, 852-860.	1.9	9
252	The Relationship between Defective Heparin Cofactor Activities and Thrombotic Phenomena in AT III Abnormalities. Thrombosis and Haemostasis, 1988, 59, 121-121.	3.4	9

#	Article	IF	CITATIONS
253	Mechanisms of thrombosis in pancreatic ductal adenocarcinoma. Best Practice and Research in Clinical Haematology, 2022, 35, 101346.	1.7	9
254	Protein C, factor VII and prothrombin time as early markers of liver function recovery or failure after liver transplantation. Blood Coagulation and Fibrinolysis, 1993, 4, 863-867.	1.0	8
255	Homozygous factor V-deficient patients show resistance to activated protein C whereas heterozygotes do not. Blood Coagulation and Fibrinolysis, 1994, 5, 825-827.	1.0	8
256	Patients with APC Resistance Compared with Those with Other Clotting Inhibitor Deficiencies Show Later Onset of Venous Thrombosis During Oral Contraception. Clinical and Applied Thrombosis/Hemostasis, 1995, 1, 274-276.	1.7	8
257	Screening for thrombophilia in children: a puzzling decision with unclear implications. Journal of Thrombosis and Haemostasis, 2004, 2, 1193-1194.	3.8	8
258	"Hypocoagulable―thromboelastography profiles in patients with cyanotic congenital heart disease: Facts or technical artifacts?. International Journal of Cardiology, 2013, 168, 2914.	1.7	8
259	Predictors of postoperative bleeding in children undergoing cardiopulmonary bypass: A preliminary Italian study. Thrombosis Research, 2017, 153, 85-89.	1.7	8
260	The Neglected Role of Bile Duct Epithelial Cells in NASH. Seminars in Liver Disease, 2022, 42, 034-047.	3.6	8
261	Effects of Glycosaminoglycans and Protamine Chloridrate on Platelet Aggregation Induced by Collagen and Thrombin. Angiology, 1989, 40, 170-174.	1.8	7
262	Combined inherited protein s and heparin co-factor II deficiency in a patient with upper limb thrombosis: A family study. Thrombosis Research, 1992, 67, 23-30.	1.7	7
263	Hereditary protein C deficiency associated with riboflavinâ€responsive lipid storage myopathy. European Journal of Neurology, 1996, 3, 61-65.	3.3	7
264	Recurrent thromboembolism in fertile women with venous thrombosis: incidence and risk factors. Thrombosis and Haemostasis, 2003, 90, 964-966.	3.4	7
265	AN UPDATED CLASSIFICATION OF FACTOR XIII DEFECT. British Journal of Haematology, 2008, 77, 565-566.	2.5	7
266	Potential Role of Thrombelastography in the Monitoring of Acquired Factor VIII Inhibitor Hemophilia A: Report on a 78-year-old Woman With Life-threatening Bleedings. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 470-476.	1.7	7
267	Effect on Thrombin Generation of the "In Vitro―Addition of Low-Dose LMWH to Plasma of Healthy Pregnant and Nonpregnant Women. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 331-333.	1.7	7
268	Factor VIIa-antithrombin complexes in patients with non-neoplastic portal vein thrombosis with and without cirrhosis. International Journal of Laboratory Hematology, 2013, 35, 101-105.	1.3	7
269	Thrombin Activatable Fibrinolysis inhibitor in Cancer Patients with and without Venous Thromboembolism. Thrombosis Research, 2013, 132, 484-486.	1.7	7
270	Management of severe bleeding in a ruptured extrauterine pregnancy. Blood Coagulation and Fibrinolysis, 2014, 25, 176-179.	1.0	7

#	Article	IF	CITATIONS
271	ABO blood group and the risk of post-thrombotic syndrome. Annals of Hematology, 2018, 97, 1057-1060.	1.8	7
272	Incidence of VTE in asymptomatic children with deficiencies of antithrombin, protein C, and protein S: a prospective cohort study. Blood Advances, 2020, 4, 5442-5448.	5.2	7
273	Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs. European Journal of Internal Medicine, 2020, 80, 73-77.	2.2	7
274	Immunization with Pentraxin3 prevents transition from subclinical to clinical lupus nephritis in lupus-prone mice: Insights from renal ultrastructural findings. Journal of Autoimmunity, 2020, 111, 102443.	6.5	7
275	Paediatric venous thromboembolism: a report from the Italian Registry of Thrombosis in Children (RITI). Blood Transfusion, 2018, 16, 363-370.	0.4	7
276	Risk Factors of Venous Thromboembolism in Noncritically III Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation. Viruses, 2022, 14, 737.	3.3	7
277	Systemic Catheter-Related Venous Thromboembolism in Children: Data From the Italian Registry of Pediatric Thrombosis. Frontiers in Pediatrics, 2022, 10, 843643.	1.9	7
278	State-of-the-Art Review: Low Incidence of Venous Thrombosis in Homozygous Patients with NT 20210 G to a Prothrombin Polymorphism. Clinical and Applied Thrombosis/Hemostasis, 1999, 5, 205-207.	1.7	6
279	Early cerebral sinovenous thrombosis in a child with acute lymphoblastic leukemia carrying the prothrombin G20210A variant. Blood Coagulation and Fibrinolysis, 2005, 16, 43-49.	1.0	6
280	Factor V Leiden pseudoâ€homozygotes have a more pronounced hypercoagulable state than factor V Leiden homozygotes. Journal of Thrombosis and Haemostasis, 2011, 9, 864-867.	3.8	6
281	Prothrombin Mutation Conveying Antithrombin Resistance. New England Journal of Medicine, 2012, 367, 1069-1070.	27.0	6
282	Endocytosis of exogenous factor V by <i>exâ€vivo</i> differentiated megakaryocytes from patients with severe parahaemophilia. British Journal of Haematology, 2016, 175, 517-524.	2.5	6
283	Short-term exposure to high levels of air pollution (nickel) and the risk of acute unprovoked proximal deep vein thrombosis in the legs. Internal and Emergency Medicine, 2016, 11, 159-162.	2.0	6
284	Hemostatic Findings in Ascitic Fluid: A Cross‣ectional Study in 70 Dogs. Journal of Veterinary Internal Medicine, 2017, 31, 43-50.	1.6	6
285	Hemostatic findings of pleural fluid in dogs and the association between pleural effusions and primary hyperfibrino(geno)lysis: A cohort study of 99 dogs. PLoS ONE, 2018, 13, e0192371.	2.5	6
286	Viscoelastic testing in oncology patients (including for the diagnosis of fibrinolysis): Review of existing evidence, technology comparison, and clinical utility. Transfusion, 2020, 60, S86-S100.	1.6	6
287	The risk of arterial thrombosis in carriers of natural coagulation inhibitors: a prospective family cohort study. Internal and Emergency Medicine, 2021, 16, 997-1003.	2.0	6
288	Susoctocog-alfa (Obizur) in the treatment of nine elderly patients with acquired haemophilia A: an Italian multicentre real world experience. Blood Transfusion, 2020, 18, 312-321.	0.4	6

#	Article	IF	CITATIONS
289	Risk Factors for Post-Thrombotic Syndrome in Patients With a First Proximal Deep Venous Thrombosis Treated With Direct Oral Anticoagulants. Angiology, 2022, 73, 649-654.	1.8	6
290	Assessing Clinically Meaningful Hypercoagulability after COVID-19 Vaccination: A Longitudinal Study. Thrombosis and Haemostasis, 2022, 122, 1352-1360.	3.4	6
291	Intracranial Haemorrhage in Haemophilia Patients Is Still an Open Issue: The Final Results of the Italian EMO.REC Registry. Journal of Clinical Medicine, 2022, 11, 1969.	2.4	6
292	Susoctocog-alfa (Obizur) in the treatment of nine elderly patients with acquired haemophilia A: an Italian multicentre real world experience. Blood Transfusion, 2020, , .	0.4	6
293	Reply to "Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis― Platelets, 2022, 33, 1104-1106.	2.3	6
294	A protein S functional assay yields unsatisfactory results in patients with activated protein C resistance. Blood Coagulation and Fibrinolysis, 1995, 6, 286.	1.0	5
295	Prevalence of Antiphospholipid Antibodies and Lupus Anticoagulant in Juvenile Patients with Objectively Documented Deep-vein Thrombosis. Clinical and Applied Thrombosis/Hemostasis, 1996, 2, 69-73.	1.7	5
296	Factor V antigen levels in APC resistance, in factor V deficiency and in combined APC resistance and factor V deficiency (pseudohomozygosis for APC resistance). Blood Coagulation and Fibrinolysis, 1997, 8, 245-248.	1.0	5
297	Clinical and laboratory expression of associated thrombophilic conditions (homozygous/heterozygous factor V Leiden mutation and heterozygous prothrombin variant 20210A) in an Italian family. Blood Coagulation and Fibrinolysis, 2000, 11, 379-384.	1.0	5
298	The steady two-dimensional flow over a rectangular obstacle lying on the bottom. Journal of Mathematical Analysis and Applications, 2008, 342, 1467-1480.	1.0	5
299	Modulating thrombotic diathesis in hereditary thrombophilia and antiphospholipid antibody syndrome: a role for circulating microparticles?. Clinical Chemistry and Laboratory Medicine, 2017, 55, 934-943.	2.3	5
300	Circulating microparticles in pregnant patients with primary anti-phospholipid syndrome: an exploratory study. Scandinavian Journal of Rheumatology, 2018, 47, 501-504.	1.1	5
301	Padua FIXa resistance to Protein S and a potential therapy for hyperactive FIXa. Thrombosis Research, 2018, 170, 133-141.	1.7	5
302	The sudden and unexpected appearance of inhibitors in a previously treated severe haemophilia B patient after the switch to albutrepenonacog alpha. Haemophilia, 2018, 24, e372-e375.	2.1	5
303	How haemophilia A impacts severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) treatment: a case report. Journal of Thrombosis and Thrombolysis, 2020, 50, 795-798.	2.1	5
304	Acquired haemophilia A, concomitant acute myocardial infarction and urgent major surgery: How to successfully treat a critical patient with rpFVIII (Obizur®). Thrombosis Research, 2020, 195, 125-127.	1.7	5
305	Hepatic benefits of HCV cure: Don't forget coagulation!. Journal of Hepatology, 2021, 74, 967-968.	3.7	5
306	Hereditary heparin cofactor II deficiency and thrombosis: report of six patients belonging to two separate kindreds. Blood Coagulation and Fibrinolysis, 1990, 1, 351-6.	1.0	5

#	Article	IF	CITATIONS
307	Staging the pre-procedural prophylaxis in decompensated cirrhosis. Digestive and Liver Disease, 2022, 54, 1130-1132.	0.9	5
308	Translational Value of Tumor-Associated Lymphangiogenesis in Cholangiocarcinoma. Journal of Personalized Medicine, 2022, 12, 1086.	2.5	5
309	Intra-cardial thrombosis with systemic and pulmonary embolism as main symptoms in a patient with protein S deficiency. Blood Coagulation and Fibrinolysis, 1992, 3, 485-488.	1.0	4
310	Prolonged oral contraceptive therapy in a woman with an antithrombin III abnormality involving heparin binding (Type lie) without thromboembolic complications. Blood Coagulation and Fibrinolysis, 1994, 5, 313-314.	1.0	4
311	State-of-the-Art Review : G to A 20210 Prothrombin Polymorphism and Venous Thrombosis: Simple Association or Causal Relationship?. Clinical and Applied Thrombosis/Hemostasis, 2000, 6, 135-138.	1.7	4
312	Phenotype and genotype expression in pseudohomozygous R2 factor V. Blood, 2001, 98, 1988-1990.	1.4	4
313	Thrombophilia and gestational VTE. Thrombosis Research, 2009, 123, S41-S44.	1.7	4
314	Association between increased FVIIa-antithrombin complex/FVIIa ratio and pre-eclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2013, 26, 1352-1354.	1.5	4
315	Identification of a novel frameshift mutation causing a premature stop codon in a young Nigerian man with type I antithrombin deficiency. Thrombosis Research, 2013, 131, 463-465.	1.7	4
316	Role of factor V Leiden polymorphism or G20210A prothrombin variant in patients with sudden sensorineural hearing loss: A meta-analysis of the literature. Thrombosis Research, 2015, 135, 565-567.	1.7	4
317	Dabigatran in ibrutinibâ€ŧreated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases. Hematological Oncology, 2018, 36, 801-803.	1.7	4
318	The prognostic role of ThromboDynamic Index in patients with severe sepsis. Internal and Emergency Medicine, 2020, 15, 163-168.	2.0	4
319	Development of a Plasma-Based Assay to Measure the Susceptibility of Factor V to Inhibition by the C-Terminus of TFPIα. Thrombosis and Haemostasis, 2020, 120, 055-064.	3.4	4
320	Thrombin generation and thromboelastometry in monitoring the in-vitro reversal of warfarin: a comparison between 3-factor and 4-factor prothrombin complex concentrates. Blood Coagulation and Fibrinolysis, 2020, 31, 127-131.	1.0	4
321	Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood, 2000, 96, 3329-3333.	1.4	4
322	Post-operative hypercoagulable whole blood profiles in patients undergoing open thoracotomy vs video-assisted thoracoscopic surgery. Blood Transfusion, 2021, 19, 144-151.	0.4	4
323	Cardiac injury and COVID-19 associated coagulopathy in patients with acute SARS-CoV-2 pneumonia: A rotational thromboelastometry study. Advances in Medical Sciences, 2022, 67, 39-44.	2.1	4
324	Occurrence of arterial thrombosis in a cohort of patients with hereditary deficiency of clotting inhibitors. Journal of Medicine, 1992, 23, 61-74.	0.1	4

#	Article	IF	CITATIONS
325	Exogenous human α-Synuclein acts in vitro as a mild platelet antiaggregant inhibiting α-thrombin-induced platelet activation. Scientific Reports, 2022, 12, .	3.3	4
326	Discrepancies between clotting and amidolytic assay in congenital clotting disorders. Thrombosis Research, 1990, 59, 701-702.	1.7	3
327	Relevance of Inherited Risk Factors in Young Patients with Deep-Vein Thrombosis. Clinical and Applied Thrombosis/Hemostasis, 1996, 2, 55-59.	1.7	3
328	ProC Global: A New Automated Screening Assay for the Evaluation of Total Function of the Protein C System. Clinical and Applied Thrombosis/Hemostasis, 2001, 7, 351-355.	1.7	3
329	Cerebral sinus venous thrombosis with parenchymal infarcts in a newborn with severe haemophilia A and subdural haematomas. Haemophilia, 2008, 14, 1117-1121.	2.1	3
330	The hazard of comparing apples and oranges: The proper indication for the use of recombinant activated clotting factor VII in cardiac surgery. Journal of Thoracic and Cardiovascular Surgery, 2011, 142, 1588-1589.	0.8	3
331	Increased thrombin generation in liver transplant recipients: Does immunosuppressive therapy play a role?. Liver Transplantation, 2011, 17, 347-348.	2.4	3
332	Factor VIIa-antithrombin complexes plasma levels in cancer patients with and without thrombosis. Thrombosis Research, 2012, 129, 818-819.	1.7	3
333	Reprint of: Factor VIIa-AT complex plasma levels and arterial thrombosis. Thrombosis Research, 2012, 130, 141.	1.7	3
334	Factor IX-Padua enhances the fibrinolytic resistance of plasma clots. Thrombosis and Haemostasis, 2014, 111, 226-232.	3.4	3
335	Assessment of Bleeding Risk in Patients with Cirrhosis. Current Hepatology Reports, 2015, 14, 9-18.	0.9	3
336	Efficacy and safety of treatment of acute nonmalignant portal vein thrombosis with subcutaneous fondaparinux in patients with cirrhosis and marked thrombocytopenia. Digestive and Liver Disease, 2016, 48, e25-e26.	0.9	3
337	Screening and treatment of portal vein thrombosis in cirrhosis. Digestive and Liver Disease, 2017, 49, 228-229.	0.9	3
338	Association between ABO blood group and bleeding phenotype in patients with mild rare bleeding disorders. Haemophilia, 2018, 24, e428-e430.	2.1	3
339	Enhanced fibrinolysis detection in a natural occurring canine model with intracavitary effusions: Comparison and degree of agreement between thromboelastometry and FDPs, D-dimer and fibrinogen concentrations. PLoS ONE, 2019, 14, e0225089.	2.5	3
340	Thrombotic risk following video-assisted thoracoscopic surgery versus open thoracotomy: a systematic review and meta-analysis. Interactive Cardiovascular and Thoracic Surgery, 2020, 30, 573-581.	1.1	3
341	MAC Project—Monitoring Anticoagulant Therapy Observational Study: Rationale and Protocol. Frontiers in Medicine, 2020, 7, 584459.	2.6	3
342	Factor V Leiden paradox and the occurrence of distal vein thrombosis in a large cohort of thrombotic patients. Thrombosis Research, 2017, 156, 20-22.	1.7	3

#	Article	IF	CITATIONS
343	Detection and characterization of seven novel protein S (PROS) gene lesions: evaluation of reverse transcript-polymerase chain reaction as a mutation screening strategy. Blood, 1995, 86, 2632-41.	1.4	3
344	Heterozygous Protein C Deficiency Associated with Multiple Congenital Hemangiomas—A Case Report. Angiology, 1991, 42, 337-342.	1.8	2
345	Are oral contraceptives a more important risk factor than pregnancy in women with congenital antithrombin III deficiency?. Blood Coagulation and Fibrinolysis, 1993, 4, 841-842.	1.0	2
346	Oral contraceptive therapy causes an increased and not a decreased resistance to APC. Blood Coagulation and Fibrinolysis, 1995, 6, 143.	1.0	2
347	Pitfalls of protein C assays in patients with activated protein C resistance. Blood Coagulation and Fibrinolysis, 1996, 7, 712-713.	1.0	2
348	91. Factor Va plays a major role in determining the fibrinolytic potential of a clot. Fibrinolysis, 1996, 10, 28.	0.5	2
349	Sex-related type of venous thromboembolism in patients with and without thrombophilia. Thrombosis and Haemostasis, 2009, 102, 177-178.	3.4	2
350	P.28 Factor V Leiden, PT-G20210A, MTHFR C677T mutations and the risk of implantation failure in women undergoing assisted reproductive procedures (IVF or ICSI). Thrombosis Research, 2011, 127, S135-S136.	1.7	2
351	Thrombosis risk in purely obstetric APS. Blood, 2012, 119, 2435-2436.	1.4	2
352	Platelet factor V levels in moderate to severe congenital factor V deficiency. Haemophilia, 2012, 18, e53-5.	2.1	2
353	235 PREDICTORS OF RESPONSE TO ANTICOAGULANT THERAPY FOR THE TREATMENT OF PORTAL VEIN THROMBOSIS (PVT) IN CIRRHOSIS PATIENTS. Journal of Hepatology, 2013, 58, S101.	3.7	2
354	Factor IX activity/antigen ratio and the risk of first unprovoked venous thromboembolism. Thrombosis and Haemostasis, 2013, 109, 755-756.	3.4	2
355	Dalteparin for pregnant women with thrombophilia. Lancet, The, 2015, 385, 688-689.	13.7	2
356	Peculiar laboratory phenotype/ genotype relationship due to compound inherited protein C defects in a child with severe venous thromboembolism. Hamostaseologie, 2018, 38, 33-38.	1.9	2
357	Tailored prophylaxis with rFXIII (NovoThirteen [®]) in a young girl with severe FXIII deficiency and previous cephalohaematoma. Haemophilia, 2019, 25, e206-e208.	2.1	2
358	Fondaparinux vs low molecular weight heparin in the treatment of non malignant portal vein thrombosis in patients cirrhosis. Digestive and Liver Disease, 2019, 51, e42.	0.9	2
359	Spontaneous recurrent intracranial haemorrhage in a woman with type 2B von Willebrand disease: A clinical case and a brief literature review. Haemophilia, 2019, 25, e282-e285.	2.1	2
360	Thromboelastometry profiles after "in vitro―addition of a new plasmaâ€derived factor V concentrate to whole blood from parahaemophilia patients. Haemophilia, 2019, 25, e38-e42.	2.1	2

#	Article	IF	CITATIONS
361	Viscoelastic testing in benign hematologic disorders: Clinical perspectives and future implications of pointâ€ofâ€care testing to assess hemostatic competence. Transfusion, 2020, 60, S101-S121.	1.6	2
362	The haemostatic system in acromegaly: a single-centre case–control study. Journal of Endocrinological Investigation, 2020, 43, 1009-1018.	3.3	2
363	Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from mixed type I/III families. Haematologica, 2010, , .	3.5	2
364	Impact of Persistent Antiphospholipid Antibodies on Symptomatic Thromboembolism In Children: A Systematic Review & Meta-Analysis [Observational Studies]. Blood, 2010, 116, 3169-3169.	1.4	2
365	Detection and characterization of seven novel protein S (PROS) gene lesions: evaluation of reverse transcript-polymerase chain reaction as a mutation screening strategy. Blood, 1995, 86, 2632-2641.	1.4	2
366	A family with an abnormal protein C and a thrombotic tendency. Haematologia, 1993, 25, 25-33.	0.3	2
367	Protein C or Protein S deficiency associates with paradoxically impaired plateletâ€dependent thrombus and fibrin formation under flow. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12678.	2.3	2
368	The biological inertia of coumarin-induced pre-factors (so called PIVKAs). Thrombosis Research, 1991, 64, 627-628.	1.7	1
369	Are oral contraceptives a more important risk factor than pregnancy in women with congenital antithrombin III deficiency?. Blood Coagulation and Fibrinolysis, 1993, 4, 841-842.	1.0	1
370	Anticardiolipin antibodies, functional protein S deficiency, and fetal loss. American Journal of Hematology, 1995, 48, 65-66.	4.1	1
371	Factor V Leiden (Activated Protein C Resistance) Versus Factor V Deficiency in Padua, Italy. Clinical and Applied Thrombosis/Hemostasis, 1998, 4, 201-204.	1.7	1
372	Factor V variants, activated protein C resistance and venous thromboembolism. Blood Coagulation and Fibrinolysis, 1998, 9, 661-662.	1.0	1
373	Heterozygous carrier of G20210A prothrombin mutation used oral contraceptive treatment for 23 years without thrombotic events, and developed cerebral venous thrombosis 1 month after resumption of the medication at the age of 50. Blood Coagulation and Fibrinolysis, 2001, 12, 161-162.	1.0	1
374	A highly polymorphic microsatellite in the factor V gene is an informative tool for the study of factor V-related disorders. British Journal of Haematology, 2001, 114, 868-870.	2.5	1
375	Appropriateness of choice and interpretation of tests for thrombophilic defects: a practical experience. Clinica Chimica Acta, 2003, 333, 191-193.	1.1	1
376	Folate status and homocysteine level in Italian patients aged under 60 on oral anticoagulant therapy. Annals of Medicine, 2003, 35, 140-144.	3.8	1
377	Factor VIIa-AT complex plasma levels and arterial thrombosis. Thrombosis Research, 2011, 128, 507.	1.7	1
378	186 EFFECT OF LOW MOLECULAR WEIGHT HEPARIN (LMWH) ON THROMBIN GENERATION IN CIRRHOTIC PATIENTS AT DIFFERENT STAGES OF LIVER DISEASE. Journal of Hepatology, 2011, 54, S79-S80.	3.7	1

#	Article	IF	CITATIONS
379	Outcome of Long-Term Prophylaxis After Cerebral Hemorrhage in a Patient With Severe Hemophilia B. Clinical and Applied Thrombosis/Hemostasis, 2011, 17, 535-538.	1.7	1
380	Portal vein thrombosis in cirrhosis: Predictors of successful anticoagulation therapy. Digestive and Liver Disease, 2014, 46, e132.	0.9	1
381	Pointâ€ofâ€care management of fulminant hyperfibrinolysis in the Emergency Department after hanging trauma. Anaesthesia Cases, 2016, 4, 97-101.	0.0	1
382	Thrombin generation tests and viscoelastic testing in cirrhosis. European Journal of Anaesthesiology, 2017, 34, 36-37.	1.7	1
383	Thromboelastographic evaluation of hemostatic balance in cirrhotic patients with infection. Digestive and Liver Disease, 2017, 49, e55.	0.9	1
384	On-treatment platelet reactivity in peripheral and coronary blood in patients undergoing primary PCI for ST-segment elevation myocardial infarction (STEMI). Scandinavian Journal of Clinical and Laboratory Investigation, 2018, 78, 281-286.	1.2	1
385	SAT-115-Fondaparinux vs low molecular weight heparin in the treatment of non malignant portal vein thrombosis in patients with cirrhosis. Journal of Hepatology, 2019, 70, e681.	3.7	1
386	Acute kidney injury is associated with reversible platelet dysfunction in hospitalized patients with decompensated cirrhosis. Digestive and Liver Disease, 2020, 52, e13.	0.9	1
387	Determinants of increased thrombotic tendency in NASH cirrhosis: not there yet!. Transplant International, 2021, 34, 1325-1327.	1.6	1
388	Reply to "Acute kidney injury in patients with decompensated cirrhosis― Digestive and Liver Disease, 2021, 53, 1217-1218.	0.9	1
389	ABO blood groups and the risk of retinal vein occlusion. Internal and Emergency Medicine, 2021, 16, 1387-1390.	2.0	1
390	Impact of Inherited Thrombophilia on Symptomatic Venous Thrombo-Embolism (VTE) in Children: A Systematic Review & Meta-Analysis of 37 Studies Including 2470 Pediatric Patients Blood, 2007, 110, 3189-3189.	1.4	1
391	Antithrombin Plasma Levels and Fibtem Determination in Children with Acute Lymphoblastic Leukemia Undergoing Asparaginase Treatment. Blood, 2014, 124, 5246-5246.	1.4	1
392	Letter to the editor: Is PAlâ€1 a thrombotic biomarker in NASH cirrhosis?. Hepatology, 2022, 76, E16-E17.	7.3	1
393	Kinetics of Human Platelet Factor 4 in Rabbits Effect of Glycosaminoglycans and Protamine Sulfate. Annals of the New York Academy of Sciences, 1989, 556, 429-431.	3.8	0
394	The biological inertia of coumarin-induced pre-factors (so called PIVKAs). Thrombosis Research, 1991, 65, 627-628.	1.7	0
395	Complications of protein C deficiency in I pregnancy. Journal of Obstetrics and Gynaecology, 1996, 16, 244-245.	0.9	0
396	Antiphospholipid Antibodies Do Not Seem to Be Associated With Deep Vein Thrombosis: A Case Control Study. Clinical and Applied Thrombosis/Hemostasis, 1997, 3, 165-167.	1.7	0

#	Article	IF	CITATIONS
397	Acute oppressive chest pain in a 66-year-old woman with a recent Amplatzer device closure of patent foramen ovale. Internal and Emergency Medicine, 2007, 2, 229-230.	2.0	Ο
398	Peculiar rocket profile in the electroimmunoassay of Protein-S-deficient plasma: a clue to diagnosis?. International Journal of Laboratory Hematology, 2008, 12, 109-111.	0.2	0
399	O5 Microparticles plasma levels in women with venous thromboembolism and cancer. Thrombosis Research, 2009, 123, S132.	1.7	Ο
400	P33 Whole blood coagulation thrombelastometry (ROTEM®) profile in 19 pregnant women. Thrombosis Research, 2009, 123, S148-S149.	1.7	0
401	PO-30 Procoagulant phospholipids in patients with venous thromboembolism and cancer. Thrombosis Research, 2010, 125, S174.	1.7	0
402	PO-43 Hypofibrinolysis in patients with venous thromboembolism and cancer. Thrombosis Research, 2010, 125, S177.	1.7	0
403	PO-56 Potential contribution of microparticles to the thrombotic risk in high grade glioma. Thrombosis Research, 2010, 125, S181.	1.7	0
404	PO-58 Endothelial circulating microparticles in thromboembolism and cancer. Thrombosis Research, 2010, 125, S181-S182.	1.7	0
405	OC-10 Effect of low molecular weight heparin (LMWH) on thrombin generation in cirrhotic patients. Digestive and Liver Disease, 2011, 43, S68.	0.9	0
406	0.10b Low-molecular-weight heparin for prevention of obstetric complications in carriers of factor V Leiden or PT-G20210A mutation. Thrombosis Research, 2011, 127, S128.	1.7	0
407	P.50 Effect of low dose LMWH "in vitro―addition on thrombin generation potential in healthy pregnant and non pregnant women. Thrombosis Research, 2011, 127, S141.	1.7	0
408	188 THROMBIN GENERATION IN PATIENTS WITH PORTAL VEIN THROMBOSIS (PVT) WITH AND WITHOUT CIRRHOSIS. Journal of Hepatology, 2011, 54, S80.	3.7	0
409	Circulating glial-derived and tissue factor bearing microparticles in patients with high grade glioma. Thrombosis Research, 2012, 129, S171-S172.	1.7	0
410	Factor VIIa-antithrombin complexes plasma levels in cancer patients with and without thrombosis. Thrombosis Research, 2012, 129, S174.	1.7	0
411	Secondary parenchymal and vascular changes after middle cerebral artery stroke in children. Neuroradiology, 2013, 55, 1259-1266.	2.2	0
412	P-036 Changes in plasma levels of factor VIIa-antithrombin complex during normal pregnancy and in pre-eclampsia. Thrombosis Research, 2013, 131, S86.	1.7	0
413	Different Impact on the Coagulation System of Two Continuous Flow LVADs: Axial Versus Centrifugal Flow. Journal of Heart and Lung Transplantation, 2013, 32, S177.	0.6	0
414	Hypercoagulability in cirrhotic patients with hepatocellular carcinoma (HCC) and portal vein thrombosis (PVT). Digestive and Liver Disease, 2014, 46, e138.	0.9	0

#	Article	IF	CITATIONS
415	OC.04.1 PROSPECTIVE EVALUATION OF THE CORRELATION BETWEEN HEMOSTATIC STATUS AND INCIDENCE OF PORTAL VEIN THROMBOSIS IN PATIENTS WITH LIVER CIRRHOSIS AND HEPATOCELLULAR CARCINOMA. Digestive and Liver Disease, 2014, 46, S11.	0.9	0
416	Hemostatic status and portal vein thrombosis (PVT) in cirrhotic patients with hepatocellular carcinoma (HCC). Digestive and Liver Disease, 2014, 46, e36.	0.9	0
417	O32 PROSPECTIVE EVALUATION OF THE CORRELATION BETWEEN HEMOSTATIC ALTERATIONS AND INCIDENCE OF PORTAL VEIN THROMBOSIS IN PATIENTS WITH LIVER CIRRHOSIS AND HEPATOCELLULAR CARCINOMA. Journal of Hepatology, 2014, 60, S14.	3.7	0
418	Circulating microparticles and risk of portal vein thrombosis in patients with liver cirrhosis and hepatocellular carcinoma. Digestive and Liver Disease, 2016, 48, e37.	0.9	0
419	Whole Blood Coagulation Tests are not Equally able to Detect Haemostatic Prothrombotic Alterations in Patients with Liver Cirrhosis and Hepatocellular Carcinoma: Rotational Thromboelastometry versus Thrombingeneration Test. Journal of Hepatology, 2016, 64, S246.	3.7	0
420	OC.03.7 CIRCULATING MICROPARTICLES AND RISK OF PORTAL VEIN THROMBOSIS IN PATIENTS WITH LIVER CIRRHOSIS AND HEPATOCELLULAR CARCINOMA. Digestive and Liver Disease, 2016, 48, e82.	0.9	0
421	Prothrombotic microparticles and risk of portal vein thrombosis in patients with HCV-related liver cirrhosis who underwent DAA antiviral therapy. Digestive and Liver Disease, 2017, 49, e9.	0.9	0
422	Local prothrombotic state in portal venous system in cirrhosis. Digestive and Liver Disease, 2017, 49, e16.	0.9	0
423	Decreased hypercoagulable state in hepatitis C virus-cirrhotic patients treated with DAA: the outcome revolution. Journal of Hepatology, 2017, 66, S122.	3.7	0
424	Hyperfibrinolysis during liver transplantation detected by classical parameters and thromboelastometry. Journal of Hepatology, 2017, 66, S195.	3.7	0
425	Study of the endothelial dysfunction in patients with gastro-intestinal cancer: preliminary results. Thrombosis Research, 2018, 164, S226.	1.7	0
426	Circulating microparticles and thrombotic risk in patients with HCV-related cirrhosis who underwent DAA treatment. Journal of Hepatology, 2018, 68, S538-S539.	3.7	0
427	Predictors of cancer-associated thrombosis in gastro-intestinal cancer: preliminary results. Thrombosis Research, 2018, 164, S199-S200.	1.7	0
428	New generation flow-cytometry to measure circulating microvesiscles in cancer. Thrombosis Research, 2018, 164, S242-S243.	1.7	0
429	The diagnostic challenge: are we missing pulmonary embolism diagnosis in patients with syncope?. Internal and Emergency Medicine, 2018, 13, 965-969.	2.0	0
430	O007: Type of combined contraceptives and the risk of venous thromboembolism in antithrombin, protein C and protein S deficient women: a prospective cohort study. Thrombosis Research, 2019, 175, S3.	1.7	0
431	Portal endothelial damage in cirrhosis. Digestive and Liver Disease, 2019, 51, e9-e10.	0.9	0
432	Heparin challenge test in patients undergoing cardiac surgery: dealing with heparin allergy. Blood Coagulation and Fibrinolysis, 2020, 31, 165-169.	1.0	0

#	Article	IF	CITATIONS
433	Edoxaban for the Longâ€Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?. Clinical and Translational Science, 2021, 14, 335-342.	3.1	0
434	Increased platelet aggregation in patients with cirrhosis and hepatocellular carcinoma: A new potential therapeutic target?. Digestive and Liver Disease, 2021, 53, S37-S38.	0.9	0
435	Unmet needs in basic and translational research in Cholangiocarcinoma. Liver Cancer International, 0, , .	1.3	0
436	Combinations of 4 mutations (FV R506Q, FV H1299R, FV Y1702C, PT 20210G/A) affecting the prothrombinase complex in a thrombophilic family. Blood, 2000, 96, 1443-1448.	1.4	0
437	Isolation and Characterization of an Antifactor VIII Antibody from a Patient with Acquired Hemophilia A and a Severe Hemorrhagic Syndrome Blood, 2006, 108, 4073-4073.	1.4	0
438	Impact of Thrombophilia On Arterial Ischemic Stroke or Cerebral Venous Sinus Thromboses in Children: A Systematic Review & Meta-Analysis of Observational Studies Blood, 2009, 114, 3993-3993.	1.4	0
439	D-Dimer Evaluation of Hemorrhagic Orbital Lymphangioma. Journal of Pediatric Ophthalmology and Strabismus, 2010, 47, 174-177.	0.7	0
440	Protein S As a Potential Treatment for FIX-Derived Deep Vein Thrombosis. Blood, 2015, 126, 2277-2277.	1.4	0
441	Could Hemorrhagic and Thrombotic Risk Due to Peg-Asparaginase be Identified By Coagulative Tests Using Fibtem and Antithrombin Levels? A Single Centre Study. Blood, 2015, 126, 2305-2305.	1.4	0
442	New Functional Assays to Selectively Quantify APC- and TFPI-Cofactor Activities of Protein S in Plasma. Blood, 2016, 128, 717-717.	1.4	0
443	Characterization of Microparticles in the lung of smokers. , 2018, , .		0
444	A Plasma-Based Assay to Measure the Susceptibility of Factor V(a) to Inhibition By TFPIα. Blood, 2018, 132, 1168-1168.	1.4	0
445	Exosomes are differentially present in bronchoalveolar lavage (BAL) of smokers and patients with COPD and IPF. , 2019, , .		0
446	Cross-talk between coagulation and inflammation in COPD. The role of Factor XIII. , 2020, , .		0
447	Deep vein thrombophlebitis of a leg in a young female with heterozygous protein C deficiency taking oral contraceptives. Folia Haematologica: Internationales Magazin FA¼r Klinische Und Morphologische Blutforschung, 1990, 117, 443-5.	0.0	0
448	Abnormal propeptide processing resulting in the presence of two abnormal species of protein C in plasma: characterization of the dysfunctional protein C Padua3 (protein C(R-1L/propeptide)). Thrombosis and Haemostasis, 2001, 86, 1017-22.	3.4	0
449	Obstetric Antiphospholipid Syndrome. , 0, , .		0